These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD. McGough JJ, Biederman J, Wigal SB, Lopez FA, McCracken JT, Spencer T, Zhang Y, Tulloch SJ. J Am Acad Child Adolesc Psychiatry; 2005 Jun; 44(6):530-8. PubMed ID: 15908835 [Abstract] [Full Text] [Related]
8. Bioavailability of triple-bead mixed amphetamine salts compared with a dose-augmentation strategy of mixed amphetamine salts extended release plus mixed amphetamine salts immediate release. Ermer JC, Shojaei A, Pennick M, Anderson CS, Silverberg A, Youcha SH. Curr Med Res Opin; 2007 May; 23(5):1067-75. PubMed ID: 17519073 [Abstract] [Full Text] [Related]
15. A community assessment, open-label study of the safety, tolerability, and effectiveness of mixed amphetamine salts extended release in school-age children with ADHD. Ambrosini PJ, Sallee FR, Lopez FA, Shi L, Michaels MA, LADD.CAT Study Group. Curr Med Res Opin; 2006 Feb; 22(2):427-40. PubMed ID: 16466615 [Abstract] [Full Text] [Related]
16. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study. Spencer TJ, Abikoff HB, Connor DF, Biederman J, Pliszka SR, Boellner S, Read SC, Pratt R. Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455 [Abstract] [Full Text] [Related]
18. A randomized, double-blind, 3-way crossover, analog classroom study of SHP465 mixed amphetamine salts extended-release in adolescents with ADHD. Wigal S, Lopez F, Frick G, Yan B, Robertson B, Madhoo M. Postgrad Med; 2019 Apr; 131(3):212-224. PubMed ID: 30681017 [Abstract] [Full Text] [Related]
19. Medication use in adults with attention deficit/hyperactivity disorder in a commercially-insured population in the United States. Zhou Z, Zhou ZY, Kelkar SS, Sikirica V, Xie J, Grebla R. Curr Med Res Opin; 2018 Apr; 34(4):585-592. PubMed ID: 29186993 [Abstract] [Full Text] [Related]